The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Expanding indications for a CLDN18.2-specific CAR T-cell therapy in GI cancers
Gregory P. Botta, MD, PhD, UC San Diego Medical Center, San Diego, CA, comments on future research in claudin 18.2 (CLDN18.2)-specific chimeric antigen receptor (CAR) T-cell therapy, which has been assessed in in patients with advanced gastric and pancreatic adenocarcinoma in a phase I trial (NCT04404595). The findings from the trial are currently being processed and the future phase II trial may include patients with biliary tract cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
